MWNA
SNDX icon

Marshall Wace North America’s Syndax Pharmaceuticals SNDX Stock Holding History

Marshall Wace North America’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-24,190
Closed -$541K – 1750
2021
Q1 		$541K Sell
24,190
-91,132
-79% -$2.06M ﹤0.01% 1179
2020
Q4 		$2.56M Buy
+115,322
New +$2.39M 0.01% 693

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's SNDX Position: Q2 2021 in Review

Marshall Wace North America sold out of Syndax Pharmaceuticals (SNDX) in Q2 2021, closing a stake of 24,190 shares — an estimated $541K sold.

Marshall Wace North America first reported a position in SNDX in Q4 2020 and held it in 2 quarters. The position peaked at $2.56M in Q4 2020. 115 funds tracked by Wall St. Rank hold SNDX as of Q2 2021.

  • Marshall Wace North America reported no remaining Syndax Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 24,190 Syndax Pharmaceuticals shares in Q2 2021, an estimated $541K.
  • Marshall Wace North America first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Marshall Wace North America's Syndax Pharmaceuticals position peaked at $2.56M in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.